Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bortezomib Booms For Stada As Russian Problem Remains

Turnaround Strategy Is In The Works In Russia

Executive Summary

With group sales rising by double digits in 2019, Stada says it has the firepower to accelerate investment not only in the firm’s own product development but also broadly into external co-development and product in-licensing, to support sustainability and long-term growth.

You may also be interested in...



Stada Says Teriparatide Roll-Out Has Been Successful

Seven months after introducing its teriparatide biosimilar to Eli Lily’s Forsteo into many European markets, Stada is pleased with results and says doctors and patients alike have responded well.

Sandoz’ Eder Heads Russia For Stada

Stada has announced the appointment of former Sandoz Germany head Stephan Eder to lead its business in Russia and the CIS. The appointment comes as Stada has just closed a $660m consumer healthcare acquisition with Takeda in the region.

Alvotech And Stada Make Biosimilars Pact

Alvotech and Stada have struck a deal that will give Stada exclusive rights to sell seven Alvotech biosimilars “in all key European markets” as well as certain other territories.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149713

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel